Navigation Links
Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel

TARRYTOWN, N.Y., Aug. 22 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Paul Lubetkin has been appointed to the position of Vice President and General Counsel, effective September 4, 2007. Mr. Lubetkin will be responsible for the overall planning, management and execution of the legal function, including global intellectual property, transactional legal advice, securities and funding, and commercial transactions. Mr. Lubetkin will report directly to Michael V. Novinski, President and Chief Executive Officer. Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology.

"Paul Lubetkin's understanding of business and legal issues, coupled with his deep knowledge of pharmaceutical law, make him an ideal fit for Emisphere," said Michael V. Novinski, President and Chief Executive Officer of Emisphere Technologies, Inc. "Mr. Lubetkin also brings a real expertise in Regulatory, SEC and Corporate Governance aligned with strong management capabilities. We are very excited to have him bring this wealth of experience to Emisphere."

Mr. Lubetkin is the previous Vice President and General Counsel of Aptuit, Inc., a private global contract research organization providing services to the pharmaceutical and biotechnology industries. He was previously Senior Vice President, General Counsel and Secretary of Odyssey Pharmaceuticals, Inc., a specialty pharmaceuticals company, where he managed litigation, negotiated and supervised material transactions, and provided a wide range of corporate and compliance advice. He is the former Senior Vice President and General Counsel of CollaGenex Pharmaceuticals, Inc., a publicly traded specialty pharmaceuticals company focused on the dermatology market, and Senior Vice President, General Counsel, and Secretary of PersonalPath Systems, Inc., a private care management and internet health business that was purchased in 2003.

His prior experience also includes a decade as Vice President, General Counsel, and Secretary of Regeneron Pharmaceuticals, Inc., a publicly traded biotechnology company and a decade of working as a trial lawyer in private practice and in the Division of Enforcement of the U.S. Securities and Exchange Commission (SEC). During Mr. Lubetkin's in-house career in the healthcare industry, he has provided counsel about corporate, corporate governance, compliance, intellectual property, litigation, transactions, and many other areas.

"This is a very exciting time to join the Emisphere team. There is a robust pipeline and the Company stands poised to improve the lives of countless patients," said Mr. Lubetkin. "I am eager to start building the foundation of their legal function and help move the company forward."

Mr. Lubetkin received his J.D. (with distinction) at the University of Iowa College of Law, Iowa City, Iowa, and his B.S. from Northwestern University, Evanston, Illinois. He is a member of the American Bar Association, the Association of Corporate Counsel, and various state bar associations. He is also a trustee of the Gateway School of New York, an accredited independent school for learning disabled children between the ages of six and 12.

Emisphere's broad-based drug delivery technology platform, known as the eligen(R) technology, is based on the use of proprietary, synthetic chemical compounds, known as Emisphere(R) delivery agents, or "carriers." Emisphere's eligen(R) technology makes it possible to deliver a therapeutic molecule without altering its chemical form or biological integrity.

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology. These molecules and compounds could be currently available or are in pre-clinical or clinical development. Such molecules or compounds usually cannot be delivered by the oral route of administration or the benefits of these compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The Web site is:

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758).

SOURCE Emisphere Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... in cat and human plaque and pave the way for ... health problems in cats     ... the most commonly diagnosed health problems in cats, yet relatively ... until now. Two collaborative studies have been conducted by researchers ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):